NCT03832621View on ClinicalTrials.gov

NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

March 25, 2019

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Temozolomide

temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks

DRUG

Nivolumab

nivolumab 480 mg i.v. every 4 weeks

DRUG

Ipilimumab

low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks

Trial Locations (1)

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

All Listed Sponsors
lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

NCT03832621 - NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter